15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Ovid Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $4.00 to $7.00, a moderate spread. The average target of $5.50 sits 133% above the current $2.36. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Ovid Therapeutics Inc.
As of Jul, 6 of 6 firms rate OVID a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
OVID EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.13 – $-0.09 · 7 analysts · -38% YoY
Next period, 7 analysts expect Ovid Therapeutics Inc to earn $-0.11 a share (range $-0.13 – $-0.09), versus $-0.17 a year earlier. Full-year consensus is $-0.44, growing to $-0.45 the year after.
REVENUE · NEXT QUARTER
$14.7K
Range $0 – $132.0K · 7 analysts · -89% YoY
Revenue is expected to reach $14.7K (range $0 – $132.0K), -88.9% year-over-year. Full-year consensus is $107.5K, rising to $166.7K next year.
Top analysts covering Ovid Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OVID.
#1
Laura Chico
Wedbush · Rank #122
Buy
$7.00+196.6% to target
Overall win rate
40%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$4.00+69.5% to target
Overall win rate
37%
+ Follow
#3
Jay Olson
Oppenheimer · Rank #302
Buy
$7.00+196.6% to target
Overall win rate
32%
+ Follow
#4
ME
Madison Elsaadi
B. Riley Securities
Buy
$5.00+111.9% to target
Coverage
—
+ Follow
#5
Ritu Baral
TD Cowen
Buy
No targeton OVID
Coverage
—
+ Follow
OVID stock forecast FAQ
What is OVID's average 12-month price target?+
The 2 analysts with a live target average $5.50 for Ovid Therapeutics Inc over the next 12 months, ranging from a $7.00 high to a $4.00 low.
Is OVID stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for OVID?+
The Street-high target is $7.00 (Wedbush), and the Street-low is $4.00 (HC Wainwright & Co.). The average of all 2 active targets is $5.50.
How many Wall Street analysts cover OVID?+
6 analysts have an active rating on Ovid Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering OVID?+
Among analysts who currently cover OVID, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #122). Their current call is Buy with a $7.00 target.
What is Ovid Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.13 – $-0.09) across 7 analysts. Full-year EPS is projected at $-0.44, rising to $-0.45 the following year.
How much revenue is Ovid Therapeutics Inc expected to report next quarter?+
Consensus revenue is $14.7K (range $0 – $132.0K). Full-year revenue is projected at $107.5K, growing to $166.7K next year.
Have analysts been upgrading or downgrading OVID lately?+
As of Jul, 6 of 6 firms rate OVID a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OVID calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
